Osteoarthritic (OA) pain represents the second largest segment of the chronic pain market and is expected to grow, driven by an aging population and the increasing prevalence of obesity. However, a comprehensively effective and tolerable analgesic class alternative has not become available for this indication in nearly two decades. A successful launch of a new analgesic requires a deep understanding of current treatment patterns in this highly generic and OTC market. Over the past few years, several new therapies have launched in the OA pain market, providing incremental safety, tolerability, and/or dosing benefits to overcome the drawbacks of the current standards of care—nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics—but how have agents in these drug classes, particularly brand-only products, fared in this highly generic market?
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed OA pain patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OA pain patients?
- How have novel branded agents such as abuse-deterrent opioid analgesics been integrated into the treatment algorithm?
- What perception of OA pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of OA pain patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with OA pain?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
Markets covered: United States.
Real-world data: Longitudinal patient-level claims data analysis.
Key companies: Purdue Pharma, Janssen, Collegium Pharmaceuticals, Horizon Pharma, and Pfizer.
Key drugs: Hysingla ER, Nucynta ER, oxycodone CR (OxyContin, generics), Vimovo, Vivlodex, Xtampza ER, and Zorvolex.
Key analysis provided:
- Brand use across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.